Observation of the clinical efficacy of propafenone and amiodarone in the treatment of mixed arrhythmias
Objective To observe the clinical efficacy of propafenone and amiodarone in the treatment of mixed arrhythmias.Methods A total of 272 patients with mixed arrhythmia were divided into a control group and an observation group according to random numerical table,with 136 cases in each group.The control group was treated with amiodarone,and the observation group was treated with propafenone+amiodarone.Both groups were compared in terms of clinical efficacy,cardiac function indicators[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),cardiac output(CO),6-min walking distance],serum inflammatory factors[interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP)],and occurrence of adverse reactions.Results The total effective rate of the observation group was 95.59%,which was significantly higher than 82.35%of the control group(P<0.05).After treatment,the observation group had LVEDD of(56.82±6.12)mm and LVESD of(43.36±5.60)mm,which were significantly lower than(61.25±6.33)and(48.22±5.47)mm in the control group;the observation group had LVEF of(55.14±5.47)%and CO of(4.75±0.48)L/min,which were significantly higher than(50.02±5.33)%and(4.10±0.45)L/min in the control group;the 6-min walking distance of(530.11±38.59)m in the observation group was significantly longer than(422.96±31.56)m in the control group(P<0.05).After treatment,the levels of hs-CRP and IL-6 in the observation group were(8.15±2.16)mg/L and(18.96±1.96)pg/ml,which were significantly lower than(12.23±3.25)mg/L and(23.10±2.03)pg/ml in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with mixed arrhythmias,the clinical efficacy of propafenone combined with amiodarone is remarkable,which facilitates the improvement of cardiac function and alleviates the inflammatory response,and is worthy of clinical adoption and promotion.